HLLY Insider Filing: CFO Jesse Weaver Receives 247,448 RSUs with 3-Year Vesting
Rhea-AI Filing Summary
Jesse Weaver, Chief Financial Officer of Holley Inc. (HLLY), was granted 247,448 restricted stock units on 08/12/2025. Each unit converts to one share upon vesting and carries no purchase price. Following the grant, Mr. Weaver beneficially owns 659,459 shares. The restricted stock units vest in approximately equal installments on August 12 of 2026, 2027 and 2028, and are subject to continued employment through each vesting date. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Long-term alignment: 247,448 RSUs vesting over three years aligns the CFO's interests with shareholders
- Retention-focused: Time-based vesting contingent on continued employment supports executive retention
Negative
- Potential dilution: Issuance of RSUs will increase outstanding shares upon vesting, though magnitude is unspecified
Insights
TL;DR: A multi-year RSU award aligns the CFO with shareholder outcomes and supports retention.
The 247,448 restricted stock unit grant is a standard long-term incentive that vests over three annual installments, tying a significant portion of the CFO's compensation to future equity performance and continued employment. The grant price is $0, consistent with RSUs rather than stock purchases. From an investor perspective, this is routine for senior executives and signals emphasis on retention and alignment rather than immediate cash payout. The size of the award relative to total outstanding shares is not specified in the filing, so absolute dilution cannot be quantified here.
TL;DR: Routine insider grant with standard vesting; governance implications limited absent further context.
The disclosure shows typical governance practice of awarding time-based RSUs to a C-suite officer, with vesting contingent on continued service. The filing includes required details: grant amount, vesting schedule, and resulting beneficial ownership of 659,459 shares. This transaction does not indicate departures, sales, or unusual executing provisions. Without additional data on total shares outstanding, grant size relative to peers or prior awards cannot be evaluated from this filing alone.